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        INTRODUCTION  
  Cortisol secretion from the adrenal zona fasciculata 
(AZF) occurs under the control of the pituitary peptide 
ACTH (adrenocorticotropic hormone) (  Simpson and 
Waterman, 1988  ). The molecular mechanisms that cou-
ple ACTH receptor activation to cortisol production are 
only partially understood. Early studies established that 
cAMP was the principal intracellular messenger for 
ACTH in AZF cells (  Haynes and Berthet, 1957  ;   Grahame-
Smith et al., 1967  ;   Richardson and Schulster, 1973  ;   Sala 
et al., 1979  ). ACTH stimulates cAMP synthesis in AZF 
cells, while cAMP mimics the steroidogenic actions of 
ACTH (Haynes et al., 1959;   Roesler et al., 1988  ;   Simpson 
and Waterman, 1988  ;   Waterman, 1994  ). Accordingly, 
bovine AZF cells express a high affi  nity, MC2-R melano-
cortin receptor coupled to adenylate cyclase through G  s   
(  Penhoat et al., 1989  ;   Raikhinstein et al., 1994  ). 
  Although cAMP appears to function as the primary 
intracellular messenger, Ca 
2+   may also act pivotally in 
ACTH-stimulated corticosteroid secretion. At concen-
trations that produce little or no measurable increase in 
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  Abbreviations used in this paper: ACTH, adrenocorticotropic hormone; 
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aminophenoxy)ethane-  N,N,N  ’  ,N  ’    ’    -tetraacetic acid; NPS-ACTH,   O  -nitro-
phenyl, sulfenyl-adrenocorticotropin.   
cAMP synthesis, ACTH has been reported to increase 
intracellular Ca 
2+   concentration and stimulate cortisol 
secretion in bovine AZF cells (  Yanagibashi et al., 1990  ; 
  Kimoto et al., 1996  ). Similarly, the   O  -nitrophenyl, sulfe-
nyl derivative of ACTH (NPS-ACTH) stimulates large 
increases in [Ca 
2+  ]  i   and corticosteroid secretion at con-
centrations that trigger no measurable increases in cAMP 
synthesis in either rat or bovine AZF cells (  Moyle et al., 
1973  ;   Yamazaki et al., 1998  ). Overall, these results sug-
gest that cAMP and Ca 
2+   are dual messengers that are 
both required to mediate the full steroidogenic response 
to ACTH. 
  In this regard, a role for electrical events and depolar-
ization-dependent Ca 
2+   entry in ACTH-stimulated corti-
sol secretion has been established (  Enyeart et al., 1993  ; 
  Mlinar et al., 1993  ). Specifi  cally, bovine AZF cells ex-
press bTREK-1 leak-type K 
+   channels, which set the rest-
ing membrane potential (  Mlinar et al., 1993  ;   Enyeart 
et al., 2002  ). ACTH receptor activation is coupled to mem-
brane depolarization and Ca 
2+   entry through the in-
hibition of bTREK-1 channels ( Enyeart et al., 1993, 1996 ; 
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  Bovine adrenal zona fasciculata (AZF) cells express bTREK-1 K 
+   channels that set the resting membrane po-
tential and function pivotally in the physiology of cortisol secretion. Inhibition of these K 
+   channels by adrenocor-
ticotropic hormone (ACTH) or cAMP is coupled to depolarization and Ca 
2+   entry. The mechanism of ACTH and 
cAMP-mediated inhibition of bTREK-1 was explored in whole cell patch clamp recordings from AZF cells. Inhibi-
tion of bTREK-1 by ACTH and forskolin was not affected by the addition of both H-89 and PKI(6  –  22) amide to the 
pipette solution at concentrations that completely blocked activation of cAMP-dependent protein kinase (PKA) in 
these cells. The ACTH derivative,   O  -nitrophenyl, sulfenyl-adrenocorticotropin (NPS-ACTH), at concentrations 
that produced little or no activation of PKA, inhibited bTREK-1 by a Ca 
2+  -independent mechanism. Northern blot 
analysis showed that bovine AZF cells robustly express mRNA for Epac2, a guanine nucleotide exchange protein 
activated by cAMP. The selective Epac activator, 8-pCPT-2  ’  -O-Me-cAMP, applied intracellularly through the patch 
pipette, inhibited bTREK-1 (IC  50   = 0.63   μ  M) at concentrations that did not activate PKA. Inhibition by this agent 
was unaffected by PKA inhibitors, including RpcAMPS, but was eliminated in the absence of hydrolyzable ATP. 
Culturing AZF cells in the presence of ACTH markedly reduced the expression of Epac2 mRNA. 8-pCPT-2  ’  -O-Me-
cAMP failed to inhibit bTREK-1 current in AZF cells that had been treated with ACTH for 3  –  4 d while inhibition 
by 8-br-cAMP was not affected. 8-pCPT-2  ’  -O-Me-cAMP failed to inhibit bTREK-1 expressed in HEK293 cells, which 
express little or no Epac2. These fi  ndings demonstrate that, in addition to the well-described PKA-dependent 
TREK-1 inhibition, ACTH, NPS-ACTH, forskolin, and 8-pCPT-2  ’  -O-Me-cAMP also inhibit these K 
+   channels by a 
PKA-independent signaling pathway. The convergent inhibition of bTREK-1 through parallel PKA- and Epac-de-
pendent mechanisms may provide for failsafe membrane depolarization by ACTH. 
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and cAMP inhibit bTREK-1 in bovine AZF cells. The 
goal of this study was to determine whether ACTH and 
cAMP could inhibit bTREK-1 by Epac2 as well as PKA-
dependent pathways. 
  Some of these results have been reported in abstract 
form (H. Liu, J.A. Enyeart, and J.J. Enyeart. 2008.   Biophys  .   J  . 
94:2181). 
  MATERIALS AND METHODS  
  Materials 
  Tissue culture media, antibiotics, fi  bronectin, and FBS were ob-
tained from Invitrogen. Coverslips were from Bellco. PBS, en-
zymes, 1,2   bis  -(2-aminophenoxy)ethane-  N,N,N  ’  ,N  ’    ’    -tetraacetic acid 
(BAPTA), MgATP, collagenase, DNase, H-89, nystatin, 8-pCPT-
cAMP, and ACTH (1  –  24), AMP-PNP, and Rp-cAMPS were obtained 
from Sigma-Aldrich. PKI(6  –  22) amide and PKI(14  –  22)myristolated 
were purchased from EMD Biosciences, Inc. 8-pCPT-2  ’  -O-Me-
cAMP (Biolog #C041) was purchased from Axxora, LLC. Human 
full-length cDNA for Epac2 (cAMP-GEFII, clone ID# 4823935) 
was purchased from Open Biosystems. p3-CD8 clone was provided 
by B. Seed (Massachusetts General Hospital, Boston, MA). Signa-
Tect cAMP-dependent protein kinase (PKA) assay system was 
from Promega. [     
32  P] ATP was purchased from Perkin Elmer. 
NPS-ACTH was custom synthesized by Celtek Peptides. 
  Isolation and Culture of AZF Cells 
  Bovine adrenal glands were obtained from steers (age 2  –  3 yr) at a 
local slaughterhouse. Isolated AZF cells were obtained and pre-
pared as previously described (  Enyeart et al., 1997  ). After isola-
tion, cells were either resuspended in DMEM/F12 (1:1) with 10% 
FBS, 100 U/ml penicillin, 0.1 mg/ml streptomycin, and the anti-
oxidants     -tocopherol (1   μ  M), 20 nM selenite, and 100   μ  M ascorbic 
acid (DMEM/F12+) and plated for immediate use, or resuspended 
in FBS/5% DMSO, divided into 1 ml aliquots, and stored in liquid 
nitrogen for future use. To ensure cell attachment, dishes were 
treated with fi  bronectin (10   μ  g/ml) at 37  °  C for 30 min and then 
rinsed with warm, sterile PBS immediately before adding cells. 
For patch clamp experiments, cells were plated in DMEM/F12+ 
in 35-mm dishes containing 9-mm 
2   glass coverslips. Coverslips 
were treated with fi  bronectin (10   μ  g/ml) as described above. 
Cells were maintained at 37  °  C in a humidifi  ed atmosphere of 
95% air  –  5% CO  2  . 
  Measurement of Epac2 mRNA 
  RNeasy columns (QIAGEN) that had been treated with RNase-
free DNase (QIAGEN) to remove genomic contamination were 
used to extract total RNA from AZF cells that had been cultured 
for 48 h both with and without ACTH (2 nM) or confl  uent HEK293 
cells. Poly(A) 
+   mRNA was extracted from total RNA using a Poly(A) 
Pure kit (Ambion). 7   μ  g of total or poly(A) 
+   mRNA were separated 
on a denaturing 8% formaldehyde, 1.0% agarose gel, and trans-
ferred to a nylon membrane (Gene Screen Plus, NEN). The RNA 
was fi  xed to the membrane by UV cross-linking using a Stratalinker 
(Stratagene). Northern blots were prehybridized in heat-sealable 
plastic bags for 2 h at 42  °  C in ULTRAhyb (Ambion) and then 
hybridized with a [      
32  P]dCTP-labeled 700-bp   XHO1   fragment of 
h-Epac2 DNA overnight at 42  °  C in minimal volume of ULTRAhyb. 
After 18  –  24 h, membrane was washed twice at room temperature 
in 2  ×   SSPE for 15 min, twice at 40  °  C in 1  ×   SSPE, 1% SDS for 
30 min, with a fi  nal wash at 40  °  C with 0.1  ×   SSPE, 1% SDS for 15 min 
before exposing to a storage phosphor screen for 4  –  12 h. North-
ern autoradiogram was imaged using a Typhoon 9200 variable 
mode phosphorimager. 
  Mlinar et al., 1993  ). Accordingly, organic Ca 
2+   antago-
nists inhibit T-type Ca 
2+   channels at concentrations that 
also inhibit ACTH-stimulated cortisol secretion (  Enyeart 
et al., 1993  ). The NPS-ACTH  –  stimulated increase in 
[Ca 
2+  ]  i   in bovine AZF cells is also inhibited by organic 
Ca 
2+   antagonists at concentrations that inhibit T-type Ca 
2+   
channels (  Yamazaki et al., 1998  ). Thus, bTREK-1 appears 
to link ACTH receptor activation to cortisol secretion 
through depolarization-dependent Ca 
2+   entry. 
  The signaling mechanisms by which ACTH inhibits 
bTREK-1 channels are incompletely understood. They 
may involve multiple cAMP- and Ca 
2+  -dependent pathways. 
Specifi  cally, neuronal TREK-1 channels are inhibited by 
cAMP through PKA-dependent phosphorylation of a 
carboxyl-terminal serine that is also present in bTREK-1 
channels (  Patel et al., 1998  ;   Honor  é  , 2007  ). Although 
native bTREK-1 channels can also be inhibited by this 
mechanism, ACTH and cAMP inhibit bTREK-1 chan-
nels in AZF cells in the presence of any of several PKA 
antagonists (  Enyeart et al., 1996  ). 
  While all of the cAMP-dependent actions of ACTH in 
AZF cells were previously thought to be mediated by 
PKA, alternative signaling pathways for cAMP-mediated 
responses are likely present in these cells. Specifi  cally, 
two cAMP-activated guanine nucleotide exchange factors, 
Epac1 and Epac2 (also known as cAMP-GEFI and cAMP-
GEFII), have been identifi  ed and implicated in the reg-
ulation of proteins including ion channels (  de Rooij et al., 
1998  ;   Kawasaki et al., 1998  ;   Holz et al., 2008  ). While 
Epac1 is expressed in many tissues, Epac2 is robustly ex-
pressed in selected areas of the brain and the adrenal 
glands of rats and humans (  Kawasaki et al., 1998  ). This 
raises the possibility that cAMP-dependent inhibition of 
bTREK-1 in the adrenal gland is mediated through sep-
arate PKA- and Epac2-dependent mechanisms. 
  In addition, studies with NPS-ACTH raise the possibil-
ity that ACTH might inhibit bTREK-1 by a Ca 
2+  -depen-
dent mechanism that is independent of both cAMP 
and PKA. In this regard, angiotensin II (AngII) which 
also stimulates cortisol secretion from bovine AZF cells, 
inhibits bTREK-1 in these cells by separate Ca 
2+  - and 
ATP-dependent pathways (  Gomora and Enyeart, 1998  ; 
  Enyeart et al., 2005  ;   Liu et al., 2007  ). Overall, our results 
and those of other investigators suggest that ACTH may 
regulate bTREK-1 channels by multiple cAMP- and Ca 
2+  -
dependent pathways. 
  In this regard, Epac1 and Epac2 possess cAMP bind-
ing domains that lack a specifi  c glutamate residue pres-
ent in the binding domain of PKA (Enserink et al., 
2002). Using this information and rational drug design, 
novel cAMP analogues were developed that, at appro-
priate concentrations, selectively activate the Epac pro-
teins (Enserink et al., 2002; Christensen et al., 2003). 
We have used one of these, 8-pCPT-2  ’  -O-Me-cAMP, along 
with other agents involved in cAMP metabolism to fur-
ther characterize the signaling pathways by which ACTH     Liu et al.  281
  Transient Transfection and Visual Identiﬁ  cation of HEK293 
Cells Expressing bTREK-1 
  For patch clamp recording of bTREK-1 currents, HEK293 cells 
were cotransfected with a mixture of pCR 
  ®   3.1-Uni-bTrek-1 and an 
expression plasmid (p3-CD8) for the      subunit of the human 
CD8 lymphocyte surface antigen at a 5:1 ratio using Lipofectamine 
(Life Technologies). Cells were visualized 1  –  2 d post transfection 
after a 15-min incubation with anti-CD8 antibody-coated beads 
(Dynal Biotech Inc.) as previously described (  Jurman et al., 1994  ). 
  RESULTS  
  Bovine AZF cells express two types of K 
+   channels: a volt-
age-gated, rapidly inactivating Kv1.4 channel, and a two 
pore domain, four transmembrane-spanning segment 
(2P/4TMS) bTREK-1 background K 
+   channel (  Mlinar 
and Enyeart, 1993  ;   Mlinar et al., 1993  ;   Enyeart et al., 2000  ; 
  Enyeart et al., 2002  ). In whole cell patch clamp record-
ings, bTREK-1 amplitude typically increases with time to 
a steady-state maximum. The absence of time- and voltage-
dependent inactivation allows bTREK-1 K 
+   currents to 
be isolated in whole cell recordings using either of two 
voltage clamp protocols. When voltage steps of several 
hundred milliseconds duration are applied from a hold-
ing potential of     80 mV, bTREK-1 K 
+   current can be 
measured near the end of a voltage step when the Kv1.4 
K 
+   current has fully inactivated (  Fig. 1, A  –  C  , left traces).   
Alternatively, bTREK-1 current can be selectively acti-
vated by an identical voltage step applied immediately 
after a 10-s prepulse to     20 mV has fully inactivated Kv1.4 
channels (  Fig. 1, A  –  C  , right traces). 
  In whole cell recordings from bovine AZF cells, we 
previously showed that ACTH inhibits bTREK-1 current 
by a mechanism that was insensitive to PKA antagonists 
H-89 and a synthetic inhibitory peptide PKI(5  –  24) when 
either was added to the recording pipette (  Enyeart 
et al., 1996  ). This result indicated that ACTH could in-
hibit bTREK-1 by a PKA-independent pathway. In the 
present study, we measured the inhibition of bTREK-1 
with the addition of a second PKI inhibitory peptide, 
PKI(6  –  22) amide, to the pipette solution, either alone 
or in combination with H-89. PKI(6  –  22) amide is a syn-
thetic peptide patterned after a portion of the naturally 
occurring PKA inhibitory peptide and inhibits PKA with 
a reported IC  50   of 1.7 nM (  Glass et al., 1989  ). When added 
to cytoplasmic extracts from AZF cells, PKI(6  –  22) am-
ide (4   μ  M) and H-89 (10   μ  M) completely inhibited PKA 
activated by maximally effective concentrations of cAMP 
(see   Fig. 7 C  ). 
  In contrast, when applied directly to the cytoplasm of 
AZF cells through the patch electrode, these PKA inhib-
itors failed to alter the potency or effectiveness of ACTH 
as an inhibitor of bTREK-1. ACTH inhibits bTREK-1 with 
an IC  50   of 4.1 pM (  Mlinar et al., 1993  ). With standard 
pipette solution, ACTH (200 pM) inhibited bTREK-1 
almost completely (95.2   ±   2.4%,   n   = 4) (  Fig. 1, A and D  ). 
The addition of PKI(6  –  22) amide (2 or 4   μ  M) to the 
  Patch Clamp Experiments 
  Patch clamp recordings of K 
+   channel currents were made in the 
whole cell and perforated patch confi  gurations from bovine AZF 
cells. The standard external solution consisted of 140 mM NaCl, 
5 mM KCl, 2 mM CaCl  2  , 2 mM MgCl  2  , 10 mM HEPES, and 5 mM 
glucose, with pH adjusted to 7.3 using NaOH. The standard pi-
pette solution consisted of 120 mM KCl, 1 mM CaCl  2  , 2 mM 
MgCl  2  , 11 mM BAPTA, 10 mM HEPES, 5 mM ATP, and 200   μ  M 
GTP, with pH titrated to 6.8 using KOH. The buffering capacity of 
pipette solutions was varied by adding combinations of CaCl  2   and 
BAPTA or EGTA using the Bound and Determined software pro-
gram (  Brooks and Storey, 1992  ). Low and high capacity Ca 
2+   buff-
ering solutions contained 0.5 mM EGTA and 11 mM BAPTA, 
respectively. The low capacity Ca 
2+   buffering solution was nomi-
nally Ca 
2+   free. [Ca 
2+  ]  i   was buffered to 22 nM in the high capacity 
buffering solution. The patch pipette solution was maintained at 
pH 6.8 to enhance the expression of bTREK-1. For perforated 
patch recordings, the pipette solution contained 130 mM KCl, 
2 mM MgCl  2  , and 20 mM HEPES, with pH adjusted to 6.8 using 
KOH. The pipette tip was fi  lled with this solution and backfi  lled 
with this same solution supplemented with 120   μ  g/ml nystatin. 
Nystatin stock solutions (30 mg/ml) were made fresh daily in 
DMSO. Perforated patch recordings were made as previously de-
scribed (  Horn and Marty, 1988  ). 
  Recording Conditions and Electronics 
  AZF cells were used for patch clamp experiments 2  –  12 h after 
plating. Typically, cells with diameters   <  15   μ  m and capacitances of 
10  –  15 pF were selected. Coverslips were transferred from 35-mm 
culture dishes to the recording chamber (volume: 1.5 ml) that 
was continuously perfused by gravity at a rate of 3  –  5 ml/min. For 
whole cell recordings, patch electrodes with resistances of 1.0  – 
2.0 M  Ω   were fabricated from Corning 0010 glass (World Precision 
Instruments). These electrodes routinely yielded access resis-
tances of 1.5  –  4.0 M  Ω   and voltage-clamp time constants of   <  100   μ  s. 
K 
+   currents were recorded at room temperature (22 –  25  °  C) accord-
ing to the procedure of Hamill et al. (  1981  ) using a List EPC-7 
patch clamp amplifi  er. 
  Pulse generation and data acquisition were done using a per-
sonal computer and PCLAMP software with Digidata 1200 interface 
(Axon Instruments, Inc.). Currents were digitized at 2  –  10 kHz after 
fi  ltering with an 8-pole Bessel fi  lter (Frequency Devices). Linear 
leak and capacity currents were subtracted from current records 
using summed scaled hyperpolarizing steps of 1/2 to 1/4 pulse 
amplitude. Data were analyzed using CLAMPFIT 9.2 (Molecular 
Devices) and SigmaPlot (version 10.0) software. Drugs were applied 
by bath perfusion, controlled manually by a six-way rotary valve. 
  PKA Assay 
  PKA activity was measured with a SignaTECT cAMP-dependent 
protein kinase assay kit (Promega). This kit uses PKA-dependent 
phosphorylation of biotinylated peptides as a measure of PKA ac-
tivity. AZF cells were plated on 60-mm fi  bronectin-treated dishes 
in DMEM/F12+ at a density of     4   ×   10 
6   cells/dish. After 24 h, the 
serum-supplemented media was removed and replaced with ei-
ther control media (DMEM/F12+) or the same media containing 
myristolyated PKI(14  –  22) and H-89. At the end of the incubation 
period, cells were washed two times with ice-cold PBS and sus-
pended in 500   μ  l of cold extraction buffer (25 mM Tris-HCl pH 
7.4, 0.5 mM EGTA, 10 mM     -mercaptoethanol, 0.5 mM Pefabloc-
SC [Roche Applied Science], and protease inhibitors with EDTA 
[Complete Mini protease inhibitor cocktail tablet, 1 per 10 ml ly-
sis solution, Roche Applied Science]). Lysates were homogenized 
using a cold Dounce homogenizer then centrifuged for 5 min at 
4  °  C at 14,000   g  . 5-  μ  l samples of lysate supernatant were assayed 
using the SignaTECT cAMP-dependent protein kinase assay sys-
tem. Each experimental condition was assayed in quadruplicate. 282   ACTH Inhibits bTREK-1 through Multiple cAMP-dependent Pathways  
nel open probability was markedly reduced only at neg-
ative potentials. 
  To determine whether ACTH or cAMP converted na-
tive bTREK-1 channels into voltage-gated channels, we 
measured bTREK-1 inhibition by ACTH (200 pM) or 
the membrane-permeable cAMP analogue 8-pCPT-cAMP 
over a wide range of test potentials. When bTREK-1 was 
activated by voltage steps between    60 and +40 mV, ACTH 
selectively inhibited this current almost completely at 
every test potential ( Fig. 2 A ).   Similarly, when bTREK-1 cur-
rents were measured in response to voltage ramps between 
    100 and +100 mV, ACTH totally inhibited this current, 
even at the most positive test potential (  Fig. 2 A  ). 
  In similar experiments, the membrane-permeable cAMP 
analogue 8-pCPT-cAMP (300   μ  M) inhibited bTREK-1 
with equal effectiveness over the same range of test volt-
ages (  Fig. 2 B  ). These results indicate that neither ACTH 
nor cAMP inhibit bTREK-1 solely by converting it to a 
voltage-gated channel through PKA phosphorylation. 
  pipette solution did not blunt ACTH-induced inhibition 
of bTREK-1 (  Fig. 1 D  ). PKI(6  –  22) amide in combina-
tion with H-89 (5 or 10   μ  M) also failed to signifi  cantly 
reduce ACTH-mediated inhibition of bTREK-1 (  Fig. 1, 
B and D  ). The PKA inhibitors were also ineffective at 
reducing bTREK-1 inhibition by ACTH at a concentra-
tion of 20 pM where   <  2% of all receptors would be acti-
vated (  Buckley and Ramachandran, 1981  ;   Raikhinstein 
et al., 1994  ) (  Fig. 1, C and D  ). 
  bTREK-1 Inhibition by ACTH and cAMP Is 
Voltage Independent 
  These results provide further proof that ACTH inhibits 
bTREK-1 by a PKA-independent mechanism. In this re-
gard, cAMP acting through PKA was reported to inhibit 
hippocampal TREK-1 channels by a mechanism that 
converted TREK-1 from a voltage-insensitive leak chan-
nel into a voltage-gated outward rectifi  er (  Bockenhauer 
et al., 2001  ). When phosphorylated by PKA, TREK-1 chan-
  Figure 1.     Effect of PKA inhibitors on bTREK-1 
inhibition by ACTH. Whole cell K 
+   currents 
were recorded from AZF cells in response to 
voltage steps applied from     80 mV at 30-s in-
tervals with or without depolarizing prepulses 
to     20 mV. Pipettes contained standard so-
lution or the same solution supplemented 
with PKI(6  –  22) amide (2 or 4   μ  M) alone or 
in combination with H-89 (5 or 10   μ  M). Af-
ter bTREK-1 reached a stable maximum, cells 
were superfused with ACTH (1 –  24) (200 pM). 
(A  –  C) K 
+   current traces recorded with (right 
traces) and without (left traces) depolarizing 
prepulses, and corresponding plot of bTREK-1 
amplitudes with (open circles) and without 
(closed circles) depolarizing pulses. Num-
bers on traces correspond to those on plots. 
(D) Summary of experiments as in A  –  C. Bars 
indicate mean   ±   SEM of bTREK-1 inhibition 
by 20 or 200 pM ACTH with or without PKA 
inhibitors as indicated.         Liu et al.  283
et al., 2007  ). The standard pipette solution containing 
5 mM MgATP with Ca 
2+   strongly buffered by 11 mM BAPTA 
facilitates selective activation of an ATP hydro  lysis-de-
pendent pathway. The Ca 
2+  -dependent pathway can be 
selectively activated with a pipette solution containing 
UTP instead of ATP, and 0.5 mM EGTA instead of 11 mM 
BAPTA (  Enyeart et al., 2005  ). 
  It was discovered that NPS-ACTH inhibited bTREK-1 
only through an ATP hydrolysis  –  dependent pathway. 
With pipette solution designed to permit selective acti-
vation of a Ca 
2+  -dependent pathway, NPS-ACTH (1 nM) 
failed to signifi  cantly inhibit bTREK-1. In contrast, AngII 
(10 nM) in these same experiments inhibited bTREK-1 by 
72.1   ±   4.2% (  n   = 3) (  Fig. 3 A  ).   With pipette solution that 
allowed selective activation of the ATP-dependent pathway, 
NPS-ACTH reversibly and completely inhibited bTREK-1 
with an IC  50   of 20.0 pM (  Fig. 3, B and C  ). 
  These results suggested that NPS-ACTH may inhibit 
bTREK-1 by the same pathways as ACTH, although less 
Overall, these fi  ndings are consistent with the hypothesis 
that ACTH inhibits bTREK-1 through separate PKA-
dependent and -independent mechanisms. 
  NPS-ACTH Inhibits bTREK-1 by a PKA- and Ca 
2+  -
independent Mechanism 
  Although our results are consistent with a model wherein 
ACTH inhibits bTREK-1 through parallel cAMP-de-
pendent paths, they do not exclude the possibility that 
inhibition could also occur through a separate Ca 
2+  -de-
pendent mechanism. 
  NPS-ACTH reportedly increases [Ca 
2+  ]  i   in bovine AZF 
cells with little or no increase in cAMP synthesis ( Yamazaki 
et al., 1998 ). This peptide was used to determine if ACTH 
could inhibit bTREK-1 by a Ca 
2+  -dependent pathway that 
is independent of cAMP. In this regard, AngII inhibits 
bTREK-1 by parallel Ca 
2+  - and ATP hydrolysis  –  dependent 
signaling pathways that can be activated separately using 
two different pipette solutions (  Enyeart et al., 2005  ;   Liu 
  Figure 2.     bTREK-1 inhibition by ACTH and 
8-pCPT-cAMP is voltage independent. bTREK-1 
was permitted to grow to a stable maximum be-
fore whole cell K 
+   currents were activated in re-
sponse to voltage steps or voltage ramps before 
and after superfusion of ACTH or 8-pCPT-cAMP. 
Voltage steps were applied at 30-s intervals in 10-mV 
increments from a holding potential of     80 mV 
to test potentials from     60 to +40 mV. Voltage 
ramps were applied at 100 mV/s to potentials 
between +100 and     100 mV from a holding po-
tential of 0 mV. (A) Effect of ACTH: K 
+   currents 
were recorded in response to voltage steps or volt-
age ramps before and after steady-state block by 
ACTH (200 pM). Top: current traces in response 
to voltage steps before and after ACTH. Bottom 
left: bTREK-1 amplitudes plotted against test 
potential before (closed circles) and after (open 
circles) ACTH. Bottom right: bTREK-1 current 
traces in response to ramp voltages before and 
after ACTH. (B, left) bTREK-1 amplitudes plot-
ted against test potential in control saline (closed 
circles) and after 8-pCPT-cAMP (open circles). 
(B, right) bTREK-1 current traces in response to 
ramp voltages before and after 8-pCPT-cAMP.     284   ACTH Inhibits bTREK-1 through Multiple cAMP-dependent Pathways  
ACTH could be indicative of a cAMP-independent, 
rather than a PKA-independent, action of cAMP. The 
di-terpene forskolin directly activates adenylate cyclase, 
increasing intracellular cAMP (  Awad et al., 1983  ). If 
cAMP inhibits bTREK-1 in AZF cells solely through 
  activation of PKA, then including PKA inhibitors in the 
recording pipette should block bTREK-1 inhibition by 
forskolin. Under control conditions, forskolin (2.5   μ  M) 
inhibited bTREK-1 current by 76.9   ±   9.3% (  n   = 4) (  Fig. 
4 A  ).   The addition of PKI(6  –  22) amide and H-89 to 
the pipette solution, at concentrations that completely 
inhibited PKA, failed to signifi  cantly reduce bTREK-1 
inhibition by forskolin (  Fig. 4, B and C  ). These fi  nd-
ings are consistent with the hypothesis that ACTH 
and cAMP inhibit bTREK-1 by the same PKA-indepen-
dent mechanism. 
  Effect of 8-pCPT-2  ’  -O-Me-cAMP on PKA Activity and 
bTREK-1 Current in Perforated Patch Recordings 
  8-pCPT-2  ’  -O-Me-cAMP has been reported to be a rela-
tively selective activator of Epac proteins. It binds to 
Epac1 with 100-fold higher affi  nity than the cyclic nu-
cleotide binding domain of the PKA regulatory subunit 
(Enserink et al., 2002; Christensen et al., 2003). When 
applied to cells in culture at concentrations up to 100   μ  M, 
potently. In this regard, the activation of PKA by ACTH 
in AZF cells serves as a remarkably sensitive measure 
of cAMP synthesis. In bovine AZF cells, ACTH activates 
PKA with an EC  50   of 1.4 pM (  Enyeart and Enyeart, 1998  ). 
We found that NPS-ACTH activated PKA in AZF cells, 
but much less potently, with an EC  50   of 336 pM (  Fig. 3 C  ). 
Although less potent than ACTH, NPS-ACTH was equally 
effective as a PKA activator at maximum concentrations 
(unpublished data). 
  These results show that NPS-ACTH increases cAMP 
synthesis in AZF cells to a level suffi  cient to activate PKA. 
However, they also indicate that bTREK-1 inhibition by 
NPS-ACTH occurs at concentrations that produce minimal 
activation of PKA. Accordingly, we found that bTREK-1 
inhibition by NPS-ACTH was not affected by including 
PKA inhibitors in the patch pipette (  Fig. 3 D  ). Overall, 
these experiments showed that NPS-ACTH increases 
cAMP synthesis in AZF cells, but can inhibit bTREK-1 by 
a PKA- and Ca 
2+  -independent mechanism. 
  Forskolin Inhibits bTREK-1 by a PKA-
independent Mechanism 
  Although all of the actions of ACTH in the adrenal 
cortex may require the synthesis of cAMP, the failure 
of PKA inhibitors to suppress bTREK-1 inhibition by 
  Figure 3.     Inhibition of 
bTREK-1 by NPS-ACTH is 
Ca 
2+   and PKA independent. 
The inhibition of bTREK-1 
in bovine AZF cells by NPS-
ACTH was measured in whole 
cell patch clamp recordings us-
ing pipette solutions that per-
mitted or blocked activation of 
Ca 
2+  , ATP, or PKA-dependent 
signaling. K 
+   currents were re-
corded at 30-s intervals in re-
sponse to voltage steps to 
+20 mV from a holding poten-
tial of     80 mV. After currents 
reached a stable maximum, 
cells were superfused with 
NPS-ACTH. (A and B) Effect 
of NPS-ACTH on bTREK-1 
through Ca 
2+  - and ATP hydro-
lysis  –  dependent pathways. 
bTREK-1 current amplitudes 
with (open circles) and without 
(closed circles) depolarizing 
prepulses are plotted against 
time. Pipette solutions con-
tained (A) 2 mM UTP, 0.5 mM 
EGTA, (B) 5 mM MgATP, 
11 mM BAPTA. NPS-ACTH and AngII were superfused at indicated times. (C) Concentration dependence of bTREK-1 inhibition and 
PKA activation by NPS-ACTH were measured in AZF cells and cell, respectively. Data were fi  t with an equation of the form (dotted line) 
I/I  MAX   = 1/[1 + (X/IC  50  ) 
B  ], where X is the NPS-ACTH concentration, and B is the Hill coeffi  cient. IC  50   is the concentration that reduces 
bTREK-1 by 50%. Values are mean   ±   SEM of indicated number of determinations, (solid line) PKA activity = 1/[1+(X/EC  50  ) 
B  ], where 
X is the NPS-ACTH concentration, and B is the Hill coeffi  cient. EC  50   is the concentration that produces 1/2 of the maximum response. 
(D) Effect of PKA inhibitors on NPS-ACTH inhibition of bTREK-1. bTREK-1 current amplitudes are plotted against time. Pipette solu-
tion contained PKI(6  –  22)amide (4   μ  M) and H-89 (10   μ  M).         Liu et al.  285
  The ineffectiveness of 8-pCPT-2  ’  -O-Me-cAMP in per-
forated patch recordings suggested that ACTH and cAMP 
do not inhibit bTREK-1 through activation of Epac2. 
However, the membrane-permeable cAMP analogue 
8-pCPT-cAMP, which potently activates PKA and Epac2 
(Christensen et al., 2003), also failed to inhibit bTREK-1 
when applied at a concentration of 30   μ  M in perforated 
patch recordings (  Fig. 5, B and C  ). In contrast, at 10-fold 
higher concentrations, 8-pCPT-cAMP inhibited bTREK-1 
by 91.2   ±   6.7 (  n   = 3) (  Fig. 5, B and C  ). These fi  ndings in-
dicate that even in perforated patch recordings, cyclic 
nucleotides applied externally fail to reach intracellular 
concentrations that are comparable to those present in 
the bath solution. 
  Inhibition of bTREK-1 by Intracellular Application of 
8-pCPT-2  ’  -O-Me-cAMP 
  Because of the limited effectiveness of the cAMP ana-
logues when applied extracellularly at low concentra-
tions and the associated uncertainty of their intracellular 
concentrations, we measured the effects of 8-pCPT-2  ’  -O-
Me-cAMP on bTREK-1 K 
+   channel activity when it was 
8-pCPT-2  ’  -O-Me-cAMP has been reported to activate 
Epac1, but not PKA (Enserink et al., 2002). However, in 
experiments on bovine AZF cells, we found that at con-
centrations   >  30   μ  M, 8-pCPT-2  ’  -O-Me-cAMP produced 
signifi  cant increases in PKA activity. When applied ex-
ternally at 100   μ  M, this cAMP analogue increased PKA 
activity approximately threefold over the control value 
(unpublished data). 
  These PKA activity measurements demonstrated that 
8-pCPT-2  ’  -O-Me-cAMP could be used in bovine AZF cells 
as a selective Epac activator at concentrations up to 30   μ  M. 
To determine whether 8-pCPT-2  ’  -O-Me-cAMP could in-
hibit bTREK-1 independently of PKA, AZF cells were 
  superfused with this agent while recording bTREK-1 cur-
rents with the nystatin perforated patch technique ( Horn 
and Marty, 1988  ). By using this technique, we hoped to 
minimize cell dialysis allowing 8-pCPT-2  ’  -O-Me-cAMP to 
reach a higher intracellular concentration. However, in 
these experiments, 8-pCPT-2  ’  -O-Me-cAMP (30   μ  M) in-
hibited bTREK-1 by only 10.2  ±   6.4% ( n   = 5), while ACTH 
(200 pM) inhibited bTREK-1 under the same conditions 
by 83.8   ±   2.8% (  n   = 7) (  Fig. 5, A and C  ).   
  Figure 4.     Effect of PKA inhibitors on bTREK-1 
inhibition by forskolin. Whole cell K 
+   currents 
were recorded from AZF cells in response to volt-
age steps applied from     80 mV at 30-s intervals 
with or without 10-s depolarizing prepulses to 
    20 mV. Patch pipettes contained standard so-
lution or the same solution supplemented with 
PKI(6  –  22) amide (4   μ  M) alone or in combi-
nation with H-89 (5 or 10   μ  M). After bTREK-1 
current reached a stable maximum, cells were 
superfused with forskolin (2.5   μ  M). (A and B) K 
+   
current traces recorded with (right traces) and 
without (left traces) prepulses, and correspond-
ing plot of bTREK-1 amplitudes with (open cir-
cles) or without (closed circles) depolarizing 
pulses. Numbers on traces correspond to those 
on plots. (C) Summary of experiments as in 
A and B. Bars indicate mean   ±   SEM of bTREK-1 
inhibition by forskolin (2.5   μ  M) with or without 
PKA inhibitors, as indicated.     286   ACTH Inhibits bTREK-1 through Multiple cAMP-dependent Pathways  
Me-cAMP activated PKA in AZF cell lystates only at con-
centrations signifi  cantly higher than those required to 
inhibit bTREK-1 current (  Fig. 7 C  ).   
  Inhibition of bTREK-1 by 8-pCPT-2  ’  -O-Me-cAMP Is 
Independent of PKA 
  The suppression of bTREK-1 expression in AZF cells 
by 8-pCPT-2  ’  -O-Me-cAMP at concentrations that induce 
little or no activation of PKA indicate that this enzyme 
does not mediate the inhibition. Accordingly, 8-pCPT-
2  ’  -O-Me-cAMP was effective in inhibiting bTREK-1 activ-
ity in the presence of PKA antagonists. 
  In the experiments illustrated in   Fig. 7 (A and B)  , AZF 
cells were preincubated for at least 30 min with the cell-
permeable PKA inhibitor myristolyated PKI(14  –  22) amide 
(4   μ  M) and H-89 (5 or 10   μ  M) before recording K 
+   cur-
rents with pipettes containing PKI(6  –  22) amide (4   μ  M) 
and H-89 (5 or 10   μ  M) with no further addition or with 
8-pCPT-2  ’  -O-Me-cAMP at several concentrations. The PKA 
inhibitors failed to suppress bTREK-1 inhibition by 8-pCPT-
2  ’  -O-Me-cAMP at concentrations from 5 to 30   μ  M 
(  Fig. 7, A and B  ). In contrast, when PKI(6  –  22) amide 
and H-89 were added to AZF cell cytoplasmic extracts, 
applied directly to the cytoplasm through the pipette. 
When applied through the pipette at concentrations from 
1 to 30   μ  M, 8-pCPT-2  ’  -O-Me-cAMP potently and effec-
tively suppressed the time-dependent growth of bTREK-1 
with an IC  50   of 0.63   μ  M (  Fig. 6, A  –  D  ).   Notably, at a con-
centration of 1   μ  M, 8-pCPT-2  ’  -O-Me-cAMP reduced 
bTREK-1 current density by 63.7% from a control value 
of 45.2   ±   5.9 pA/pF (  n   = 15) to 16.4   ±   4.4 pA/pF (  n   = 6). 
Using this low concentration of 8-pCPT-2  ’  -O-Me-cAMP 
in the pipette, bTREK-1 amplitude initially grew, but then 
declined to a steady-state value (  Fig. 6 B  ). At higher con-
centrations, the initial increase in bTREK-1 amplitude 
was absent and inhibition of bTREK-1 activity was nearly 
complete (  Fig. 6, C and D  ). The inhibition of bTREK-1 
expression by 8-pCPT-2  ’  -O-Me-cAMP was specifi  c. This 
agent did not alter the expression of the voltage-gated 
Kv1.4 current in these cells (  Fig. 6 E  ). 
  When applied intracellularly through the patch pipette, 
8-pCPT-2  ’  -O-Me-cAMP inhibited bTREK-1 at concentra-
tions similar to those that activate Epac in vitro (EC  50   = 
2.2  μ  M). By comparison, 10 –  20-fold higher concentrations 
were required to activate PKA holoenzyme (Enserink 
et al., 2002). Accordingly, we found that 8-pCPT-2  ’  -O-
  Figure 5.     Effect of 8-pCPT-cAMP on bTREK-
1 currents in perforated patch recordings. 
(A and B) Perforated patch recordings: whole 
cell K 
+   currents were recorded in the nystatin 
perforated patch confi  guration in response 
to voltage steps applied at 30-s intervals from 
a holding potential of     80 to +20 mV with 
(right traces) or without (left traces) depo-
larizing prepulses. After bTREK-1 reached a 
stable amplitude, cells were superfused with 
8-pCPT-2  ’  -O-Me-cAMP (designated EA for 
Epac activator) (30   μ  M), ACTH (200 pM), or 
8-pCPT-cAMP (30 or 300   μ  M), as indicated. 
Numbers on current traces correspond to 
those on plot at right. (C) Summary of ex-
periments as in A and B. Bars indicate mean   ±   
SEM of indicated number of determinations.         Liu et al.  287
proceeds through an ATP hydrolysis-dependent mecha-
nism, then substitution of the nonhydrolyzable ATP 
analogue AMP-PNP for ATP in the pipette solution 
should eliminate inhibition by the Epac2 activator. Ac-
cordingly, when pipette solutions contained 2 mM AMP-
PNP in place of ATP, 8-pCPT-2  ’  -O-Me-cAMP (30   μ  M) 
failed to suppress bTREK-1 expression in whole cell re-
cordings (  Fig. 7 D  ). 
  Inhibition of bTREK-1 in Twice Patched Cells by 8-pCPT-2  ’  -
O-Me-cAMP 
  In whole cell recordings, intracellularly applied 8-pCPT-
2  ’  -O-Me-cAMP suppressed bTREK-1 expression, even 
when the AZF cell had been preincubated with PKA in-
hibitors, and the patch electrode contained PKA inhibi-
tors. To further demonstrate that 8-pCPT-2 ’  -O-Me-cAMP 
inhibited bTREK-1 under conditions where PKA activity 
had been totally blocked in advance, AZF cells were 
sequentially patched with a pipette containing the PKA 
PKA activation by 8-pCPT-2  ’  -O-Me-cAMP (1  –  30   μ  M) or 
cAMP (5   μ  M) was completely inhibited to levels below 
control values (  Fig. 7 C  ). Overall, 8-pCPT-2  ’  -O-Me-cAMP 
effectively suppressed bTREK-1 channel activity under 
conditions where PKA had been completely eliminated. 
  Adenosine-3    -5    -cyclic monophosphorothioate, Rp iso-
mer (Rp-cAMPS) competitively inhibits cAMP activation 
of PKA, but not Epac, in living cells (  Holz et al., 2008  ; 
  Poppe et al., 2008  ). The presence of 500   μ  M Rp-cAMPS 
in the pipette solution failed to blunt the complete in-
hibition of bTREK-1 by 8-pCPT-2  ’  -O-Me-cAMP (30   μ  M), 
providing further evidence for an Epac2-dependent in-
hibition of bTREK-1 (  Fig. 7, A and D  ). 
  Inhibition of bTREK-1 by 8-pCPT-2  ’  -O-Me-cAMP Requires 
Hydrolyzable ATP 
  The inhibition of bTREK-1 by ACTH and 8-pCPT-cAMP 
requires hydrolyzable ATP (  Enyeart et al., 1996  ). If 8-pCPT-
2  ’  -O-Me-cAMP  –  mediated inhibition of bTREK-1 also 
  Figure 6.     Concentration-dependent inhibition 
of bTREK-1 by 8-pCPT-2  ’  -O-Me-cAMP. K 
+   cur-
rents were recorded from AZF cells with stan-
dard pipette solution or the same solution 
supplemented with 8-pCPT-2 ’  -O-Me-cAMP (EA) 
at concentrations from 1 to 30   μ  M. Currents 
were recorded in response to voltage steps to 
+20 mV applied at 30-s intervals from a hold-
ing potential of     80 mV with and without 
depolarizing prepulses. (A  –  C) Time-dependent 
increase in bTREK-1 and inhibition by 8-pCPT-
2  ’  -O-Me-cAMP (EA). Current traces recorded 
with (right) and without (left) depolarizing 
prepulses at indicated times. bTREK-1 ampli-
tudes are plotted at right. Open circles indicate 
traces recorded with depolarizing prepulse. 
(D) Summary of experiments as in A  –  C. Bars 
indicate bTREK-1 current density in pA/pF 
expressed as the mean   ±   SEM of the indicated 
number of determinations. (E) Effect of 
8-pCPT-2  ’  -O-Me-cAMP (EA) on Kv1.4 current. 
Bars indicate Kv1.4 current density in pA/pF 
expressed as the mean   ±   SEM of the indicated 
number of determinations in control saline 
and in the presence of 8-pCPT-2  ’  -O-Me-cAMP 
(30   μ  M) (EA).     288   ACTH Inhibits bTREK-1 through Multiple cAMP-dependent Pathways  
pression of bTREK-1 mRNA and K 
+   channels (  Enyeart 
et al., 2003  ). We now report that, under similar con-
ditions, ACTH markedly suppresses the expression of 
Epac2 mRNA. In the experiment illustrated in   Fig. 9 A  , 
AZF cells were treated with ACTH (2 nM) for 48 h before 
isolating mRNA.   Northern analysis showed that Epac2-
specifi  c mRNA was markedly reduced, compared with 
its time-matched control. 
  When AZF cells were exposed to ACTH (10 nM) for 
72 or 96 h before recording K 
+   currents, 8-pCPT-2  ’  -O-
Me-cAMP failed to inhibit bTREK-1 expression. In the 
experiments illustrated in   Fig. 9 B, K   
+   currents were re-
corded from ACTH-treated cells with pipettes contain-
ing either standard solution plus PKA inhibitors, or the 
same solution supplemented with 8-pCPT-2  ’  -O-Me-cAMP 
(5   μ  M). The maximum bTREK-1 current densities were 
nearly identical in the absence or presence of the Epac 
activator. In contrast, when K 
+   currents were recorded 
from ACTH-treated cells using pipettes containing 8-br-
cAMP, which activates PKA as well as Epac2, bTREK-1 
was nearly completely inhibited (  Fig. 9 B  ). 
  In other experiments, AZF cells were treated for 72  –
  96 h with ACTH (10 nM) before patch clamping them 
with pipettes containing PKA inhibitors followed by 
antagonists, followed by one containing these antago-
nists as well as 8-pCPT-2  ’  -O-Me-cAMP. 
  Control experiments showed that AZF cells could of-
ten be consecutively patched with two pipettes without 
compromising the recording of bTREK-1 currents. In 
the experiment illustrated in   Fig. 8 A  , the cell was con-
secutively patched by two pipettes containing standard 
pipette solution.   bTREK-1 current amplitude remained 
relatively constant upon voltage clamping the cell with 
the second pipette. In contrast, when the second pipette 
contained 8-pCPT-2  ’  -O-Me-cAMP (15   μ  M), bTREK-1 was 
rapidly inhibited (  Fig. 8 B  ). Similar results were obtained 
in each of four experiments. 
  Finally, when cells were fi  rst voltage clamped with pi-
pettes containing PKI (4   μ  M) and H-89 (10   μ  M) to pre-
inhibit PKA, subsequent voltage clamp of the cell with 
patch electrodes containing the PKA inhibitors as well 
as 8-pCPT-2  ’  -O-Me-cAMP produced near complete in-
hibition of bTREK-1 (  Fig. 8 C  ). 
  8-pCPT-2  ’  -O-Me-cAMP Fails to Inhibit bTREK-1 when 
Epac2 Expression Is Suppressed by ACTH 
  In a previous study, we demonstrated that prolonged 
treatment of AZF cells with ACTH enhances the ex-
  Figure 7.     bTREK-1 inhi-
bition by 8-pCPT-2  ’  -O-Me-
cAMP is independent of PKA. 
(A  –  C) Whole cell K 
+   currents 
were recorded in response to 
voltage steps applied at 30-s 
intervals from     80 to +20 mV 
with or without depolarizing 
prepulses. Pipettes contained 
standard solution or the same 
solution supplemented with 
8-pCPT-2  ’  -O-Me-cAMP (EA), 
either alone or in combina-
tion with PKA inhibitors H-89 
(10   μ  M), PKI(6  –  22) amide 
(4   μ  M), and Rp-cAMPS (500 
  μ  M), as indicated. When 
pipettes contained PKA in-
hibitors H-89 and PKI(6  –  22), 
cells were also pretreated for 
30 min with H-89 (10   μ  M) 
and myristolated PKI(14  –  22) 
peptide (4   μ  M) before initi-
ating recording. (A) Plots of 
bTREK-1 amplitude against 
time with pipettes containing 
indicated solutions. (B) Sum-
mary of experiments as in A. 
Bars indicate bTREK-1 current density in pA/pF expressed as the mean   ±   SEM of the indicated number of determinations. (C) Effect of 
8-pCPT-2  ’  -O-Me-cAMP (EA) and PKA inhibitors on PKA activity in AZF cell lysates: PKA activity was determined in cell lysates after incu-
bating AZF cells either without (untreated) or with PKA inhibitors for 30 min. PKA activity in lysates from untreated cells was measured 
after 5 min with no further addition (control) or after addition of cAMP (5   μ  M) or 8-pCPT-2  ’  -O-Me-cAMP (1  –  30   μ  M) (EA). PKA activity 
in lysates from PKA inhibitor  –  treated cells was measured after 5 min incubation with cAMP (5   μ  M) or 8-pCPT-2  ’  -O-Me-cAMP (1  –  30   μ  M) 
(EA) and the PKA inhibitors as indicated. PKA activity is expressed as % of that activatable by 5   μ  M cAMP in control lysates. (D) Effect of 
AMP-PNP on 8-pCPT-2  ’  -O-Me-cAMP inhibition of bTREK-1 current. bTREK-1 current was measured at 30-s intervals using patch pipettes 
containing AMP-PNP (2 mM) in place of ATP, or this same solution plus 8-pCPT-2  ’  -O-Me-cAMP (30   μ  M) (EA). Bars represent mean   ±   
SEM of maximum current density for the indicated number of determinations.         Liu et al.  289
of mRNA from bovine AZF cells, Epac2 was readily de-
tected. By comparison, little or no Epac2 mRNA could 
be detected in HEK293 cells (  Fig. 10 D  ).   Experiments 
were done to determine whether 8-pCPT-2  ’  -O-Me-cAMP 
could inhibit the activity of cloned bTREK-1 channels 
expressed in HEK293 cells where Epac2 is poorly ex-
pressed. In contrast to its effect in bovine AZF cells, 
the presence of 8-pCPT-2  ’  -O-Me-cAMP in the pipette 
  solution at 5 or 15   μ  M failed to alter the functional 
  expression of bTREK-1 in transfected HEK293 cells 
(  Fig. 10, A and C  ). 
  Although Epac2 may be absent from HEK293 cells, 
these cells do express functional PKA ( Rich et al., 2007 ). 
N6-benzoyl-cAMP (6-Bnz-cAMP) is a cAMP analogue that 
selectively activates PKA over Epac (Christensen et al., 
2003). When 6-Bnz-cAMP (15   μ  M) was included in the 
pipette solution, the activity of transfected bTREK-1 K 
+   
channels in HEK293 cells was markedly suppressed 
from a control value of 141.2   ±   25.8 pA/pF (  n   = 19) to 
34.5   ±   6.4 pA/pF (  n   = 9) (  Fig. 10, B and D  ). These results 
PKA inhibitors plus 8-pCPT-2  ’  -O-Me-cAMP (5   μ  M). 
Under these conditions, 8-pCPT-2  ’  -O-Me-cAMP (5   μ  M) 
failed to produce any inhibition of bTREK-1 current in 
each of four cells (  Fig. 9 C  ). In fact, maximum bTREK-1 
density was slightly increased from 26.1   ±   3.0 to 29.6   ±   
7.9 pA/pF in the presence of the Epac activator. In 
contrast, when the experiment was repeated with cells 
that had not been pretreated with ACTH, 8-pCPT-
2  ’  -O-Me-cAMP inhibited bTREK-1 by 88.1   ±   3.1% 
(  n   = 4) (  Fig. 9 D  ). 
  8-pCPT-2  ’  -O-Me-cAMP Does Not Inhibit bTREK-1 Activity 
in Transfected HEK293 Cells 
  Epac2 is robustly expressed in a limited number of tis-
sues, including the adrenal glands of rats and humans 
(  Kawasaki et al., 1998  ). However, the distribution of 
Epac2 expression within the adrenal has not been de-
termined. Specifi  cally, it hasn  ’  t been shown that Epac2 
is expressed in adrenal cortical cells, rather than neural 
crest  –  derived adrenal chromaffi  n cells. In Northern blots 
  Figure 8.     Inhibition of bTREK-1 by 8-pCPT-
2  ’  -O-Me-cAMP in twice-patched cells. Whole 
cell K 
+   currents were recorded in response to 
voltage steps to +20 mV applied at 30-s inter-
vals from     80 mV, with or without depolariz-
ing prepulses. Cells were sequentially patched 
with two pipettes containing standard solu-
tion, or the same solution supplemented with 
PKI(6  –  22) amide (4   μ  M), H-89 (10   μ  M), or 
8-pCPT-2  ’  -O-Me-cAMP (EA) as indicated. When 
bTREK-1 reached a stable maximum, the fi  rst 
pipette was withdrawn and the cell patched 
again with the second pipette. (A  –  C) Current 
traces and corresponding plots of bTREK-1 
amplitude against time for cells patch clamped 
with pipettes containing the additions indi-
cated. Closed circles represent pipette #1, 
closed triangles, pipette #2. Numbers on 
traces at left correspond to those on plot at 
right. Break in graph denotes time required 
to change patch pipettes.     290   ACTH Inhibits bTREK-1 through Multiple cAMP-dependent Pathways  
  PKA-independent Inhibition of bTREK-1 by ACTH 
and Forskolin 
  Experiments in which PKI(6  –  22) amide and H-89 failed 
to blunt bTREK-1 inhibition by ACTH or forskolin pro-
vide convincing evidence that inhibition of this channel 
by cAMP can occur through a PKA-independent mecha-
nism. PKI(6  –  22) amide was used at concentrations 
    1,000  –  2,000 times the reported IC  50   of 1.7 nM (  Glass 
et al., 1989  ). H-89, which competes with ATP for its 
binding site on PKA, was used at 100  –  200 times its re-
ported IC  50   of   <  50 nM (  Hidaka et al., 1991  ). When ap-
plied together to AZF cell cytoplasmic extracts, these 
agents eliminated the activation of PKA by 8-pCPT-2  ’  -O-
Me-cAMP or cAMP. When applied together to the cyto-
plasm through the pipette solution, these agents should 
have completely blocked PKA activation by ACTH and 
forskolin, yet bTREK-1 inhibition was not affected. 
  The voltage-independent inhibition of bTREK-1 by 
ACTH and 8-pCPT-cAMP in the presence of PKA antag-
onists provided additional evidence that this response 
show that 8-pCPT-2  ’  -O-Me-cAMP fails to inhibit bTREK-1 
activity in cells that poorly express Epac2, while these 
same channels are inhibited in response to specifi  c acti-
vation of PKA. 
  DISCUSSION  
  The major fi  ndings of this study are that ACTH, NPS-
ACTH, and cAMP inhibit bTREK-1 K 
+   channels in bo-
vine AZF cells by multiple cAMP-dependent signaling 
pathways that likely involve the activation of both PKA 
and Epac2. bTREK-1 is among the fi  rst K 
+   channels 
identifi  ed thus far that is inhibited by parallel cAMP-de-
pendent pathways. ATP-sensitive K 
+   channels of pancre-
atic      cells are also inhibited by cAMP through separate 
PKA- and Epac-dependent mechanisms (  Light et al., 
2002  ;   Kang et al., 2008  ). The convergent inhibition of 
bTREK-1 K 
+   channels by these two cAMP-dependent 
mechanisms provides for effi  cient fail-safe depolariza-
tion of AZF cells by ACTH. 
  Figure 9.     Effect of suppression of Epac2 
expression on bTREK-1 inhibition by 8-pCPT-
2  ’  -O-Me-cAMP and 8-br-cAMP. (A) Northern 
blot analysis of ACTH inhibition of Epac2 
mRNA expression. AZF cells were cultured 
either without (control) or with ACTH 
(2nM). mRNA was isolated after 48 h and ana-
lyzed as described in Materials and methods. 
(B) 8-pCPT-2  ’  -O-Me-cAMP and bTREK-1 ex-
pression in ACTH-treated cells. AZF cells were 
exposed to ACTH (10 nM) for 72  –  96 h before 
patch clamping with pipettes containing PKI 
amide (6  –  22) (4   μ  M) and H89 (10   μ  M) (con-
trol), this same solution supplemented with 
8-pCPT-2  ’  -O-Me-cAMP (5   μ  M) (EA), or a solu-
tion containing 8-br-cAMP (15   μ  M). bTREK-1 
current amplitudes are plotted against time. 
Bar graphs: summary of bTREK-1 maximum 
current densities. Values are mean   ±   SEM 
of indicated number of determinations. 
(C and D) Effect of ACTH treatment on 
bTREK-1 inhibition by 8-pCPT-2  ’  -O-Me-cAMP 
in twice-patched cells. AZF cells were cultured 
in serum-supplemented media with (C) or 
without (D) 10 nM ACTH for 72  –  96 h before 
sequentially recording K 
+   currents with pi-
pettes containing PKI amide (6  –  22) (4   μ  M) 
plus H89 (10   μ  M) and then these two agents 
plus 8-pCPT-2  ’  -O-Me-cAMP (EA) (5   μ  M). K 
+   
current traces recorded with (right traces) and 
without (left traces) depolarizing prepulses. 
Numbers on traces correspond to those on 
plots of bTREK-1 amplitude at right.         Liu et al.  291
mainly by Ca 
2+   released from intracellular sites, while 
ACTH-mediated increases in [Ca 
2+  ]  i   occur in response to 
Ca 
2+   infl  ux through voltage-gated Ca 
2+   channels (  Yamazaki 
et al., 1998  ;   Hunyady and Catt, 2005  ). In whole-cell patch 
clamp experiments where cells are voltage clamped at 
    80 mV, ACTH-stimulated infl  ux through voltage-gated 
channels would be eliminated, preempting a Ca 
2+  -depen-
dent inhibition of bTREK-1. Under physiological condi-
tions, Ca 
2+   entry through voltage-gated channels could 
contribute to ACTH-stimulated bTREK-1 inhibition and 
membrane depolarization. 
  NPS-ACTH did increase the concentration of cAMP in 
AZF cells to a level suffi  cient to activate PKA. However, 
similar to ACTH, the inhibition of bTREK-1 by NPS-
ACTH appeared not to be mediated by PKA. First, 
NPS-ACTH inhibited bTREK-1 half-maximally at a con-
centration 16-fold lower than that required for half-maxi-
mal activation of PKA. Second, TREK-1 inhibition by 
NPS-ACTH was insensitive to PKA inhibitors. Overall, 
these results are consistent with a mechanism where, 
was not mediated through PKA. Previous studies showed 
that inhibition of neuronal TREK-1 channels by PKA-
dependent phosphorylation occurred through a right-
ward shift in the voltage-dependent activation of these 
channels (  Bockenhauer et al., 2001  ;   Maingret et al., 
2002  ). Consequently, open probability was not reduced 
at positive test voltages. In AZF cells, bTREK-1 was effec-
tively inhibited by ACTH and 8-pCPT-cAMP regardless 
of test potential, suggesting the involvement of a sepa-
rate PKA-independent mechanism. 
  Ca 
2+  - and PKA-independent Inhibition of bTREK-1 
by NPS-ACTH 
  NPS-ACTH reversibly inhibited bTREK-1 current with 
an IC  50   of 20 pM. Although this peptide was reported to 
trigger step-like and repetitive spike-like increases in 
[Ca 
2+  ]  i   in bovine AZF cells (  Yamazaki et al., 1998  ), it 
failed to inhibit bTREK-1 through a Ca 
2+  -dependent 
pathway similar to that activated by AngII. In this re-
gard, AngII-stimulated increases in [Ca 
2+  ]  i   are mediated 
  Figure 10.     6-Bnz-cAMP but not 8-pCPT-
2  ’  -O-Me-cAMP inhibits bTREK-1 channels 
expressed in HEK293 cells. Whole cell K 
+   
currents were recorded from HEK293 cells 
that had been transiently transfected with 
pCR3.1 uni-bTREK-1 cDNA. K 
+   currents were 
activated by voltage steps to +20 mV, applied 
at 30-s intervals from a holding potential of 
    80 mV. Patch pipettes contained control sa-
line or this same solution supplemented with 
8-pCPT-2  ’  -O-Me-cAMP (5 or 15   μ  M) (EA) or 
6-Bnz-cAMP (15   μ  M). (A and B) Effect of 
8-pCPT-2  ’  -O-Me-cAMP (EA) and 6-Bnz-cAMP 
on bTREK-1 current. bTREK-1 current traces 
and associated time-dependent plots of cur-
rent amplitudes. Numbers on traces corre-
spond to those on plots at right. (C) Summary 
of experiments as shown in A and B. Bars 
  indicate maximum bTREK-1 current density 
expressed as pA/pF. Values are mean   ±   SEM 
for indicated number of determinations. 
(D) Northern blot analysis of Epac2 in bovine 
AZF and HEK293 cells. Lanes contained 7   μ  g 
of poly(A) 
+   RNA from the indicated cells. 
Hybridization with hEpac2 probe was performed 
as described in Materials and methods.     292   ACTH Inhibits bTREK-1 through Multiple cAMP-dependent Pathways  
the IC  50   20-fold (  Kang et al., 2008  ). bTREK-1 inhibition 
by this Epac-selective cyclic nucleotide occurs through a 
different mechanism, since inhibition is blocked when 
AMP-PNP replaces ATP in the pipette solution, indicat-
ing a requirement for ATP hydrolysis. Specifi  c protein 
kinases activated by Epac2 have not been identifi  ed. 
  The failure of membrane-permeable 8  ’  -substituted 
cAMP derivatives, including 8-pCPT-cAMP and 8-pCPT-2  ’  -
O-Me-cAMP to inhibit bTREK-1 when superfused exter-
nally at low concentrations in perforated patch recordings 
was unexpected. In perforated patch recording, whole cell 
dialysis is presumably limited when compared with stan-
dard whole cell recording. In standard whole cell record-
ing, we previously found that 8-pCPT-cAMP inhibited 
bTREK-1 channels with an IC  50   of 167   μ  M, a concentra-
tion much higher than that required to activate PKA in 
intact AZF cells (  Enyeart et al., 1996  ). Similar high con-
centrations of 8-pCPT-cAMP were also required to inhibit 
bTREK-1 in perforated patch recordings. 
  It seems likely that the reduced potency of cyclic nu-
cleotides applied externally in perforated patch recordings 
stems from limited transport across the cell membrane. 
Their potency as bTREK-1 inhibitors increased mark-
edly when they were directly applied to the cytoplasm 
through the patch pipette. Similar results have been seen 
in a study of the inhibition of K  ATP   K 
+   channels by Epac-
selective cAMP analogues in pancreatic      cells (  Kang 
et al., 2006  ). 
  Overall, the selectivity of 8-pCPT-2  ’  -O-Me-cAMP as an 
Epac-specifi  c activator may have been overstated in the 
initial studies of this and similar compounds (Enserink 
et al., 2002; Christensen et al., 2003;   Rehmann et al., 
2003  ). It is clear that when applied externally to intact 
cells at concentrations   >  50   μ  M, these agents produce 
signifi  cant activation of PKA and possibly other cAMP-
activated proteins. Results obtained from experiments 
where these agents were used at concentrations of 100   μ  M 
or more in the absence of PKA inhibitors should be in-
terpreted with caution. 
  Although we have found that bovine AZF cells express 
Epac2 and that an Epac-selective cAMP analogue inhib-
its bTREK-1 at low concentrations under conditions 
where PKA is inhibited, and fails to inhibit bTREK-1 in 
cells when Epac2 expression has been suppressed, the 
possibility remains that 8-pCPT-2  ’  -O-Me-cAMP inhibits 
bTREK-1 through a cAMP-binding protein different than 
PKA or Epac2. PKA- and Epac-independent actions of 
cAMP have been observed in neurons and endocrine 
cells (  Ivins et al., 2004  ;   Gambaryan et al., 2006  ). 
  Our results demonstrate that ACTH inhibits bTREK-1 
K 
+   channels in bovine AZF cells through activation of 
multiple cAMP-dependent signaling pathways. The con-
vergent inhibition of bTREK-1 through separate PKA- 
and Epac2-dependent signaling pathways provides an 
effi  cient, reliable mechanism for membrane depolariza-
tion and Ca 
2+   entry. 
similar to ACTH, NPS-ACTH can inhibit bTREK-1 by a 
PKA-independent action of cAMP. 
  Inhibition of bTREK-1 by 8-pCPT-2  ’  -O-Me-cAMP 
  8-pCPT-2  ’  -O-Me-cAMP potently and effectively inhib-
ited bTREK-1 activity when applied intracellularly 
through the patch pipette in whole cell recordings. Sev-
eral lines of evidence strongly indicate that this inhibition 
was mediated through Epac2. First, bTREK-1 expression 
was inhibited half-maximally with an IC  50   of   <  1   μ  M. This 
result is in excellent agreement with that reported for 
the potency of this agent in activating Epac1 and Epac2, 
where binding affi  nities and EC  50  s of 1  –  5   μ  M have been 
reported (Enserink et al., 2002;   Bos, 2003  ;   Rehmann 
et al., 2003  ). In contrast, 8-pCPT-2  ’  -O-Me-cAMP acti-
vates PKA only at 10  –  20-fold higher concentrations, and 
is far less effective than cAMP in this respect (Enserink 
et al., 2002;   Bos, 2003  ). 
  Further, we showed that 8-pCPT-2  ’  -O-Me-cAMP inhib-
ited bTREK-1 completely at concentrations that pro-
duced little or no measurable increase in PKA activity in 
AZF cells. This agent also effectively inhibited bTREK-1 
activity in cells where PKA had been inhibited by prein-
cubating cells with PKA inhibitors and with these inhib-
itors included in the patch pipette at concentrations 
100  –  1,000 times their reported EC  50  s. Third, 8-pCPT-2  ’  -
O-Me-cAMP inhibited bTREK-1 in twice-patched cells 
where PKA was fi  rst preinhibited by direct application 
of the two PKA inhibitors to the cytoplasm through 
the patch pipette. Finally, 8-pCPT-2  ’  -O-Me-cAMP was in-
effective at inhibiting bTREK-1 channels when Epac2 
expression had been suppressed by prolonged expo-
sure of AZF cells to ACTH, or in HEK293 cells that ex-
press little or no Epac2. In contrast, cAMP derivatives 
that activate PKA retained their effectiveness in these 
two systems. 
  It isn  ’  t known whether cAMP might also inhibit 
bTREK-1 in other cells through PKA- and Epac2-depen-
dent signaling pathways. Since the expression of Epac2 is 
limited, other cells expressing both Epac2 and bTREK-1 
have not yet been identifi  ed. It is possible that TREK-1 
inhibition through Epac2 could occur in selected CNS 
neurons that express both of these proteins. 
  Signaling Mechanism for bTREK-1 Inhibition by 8-pCPT-2  ’  -
O-Me-cAMP 
  The mechanism by which 8-pCPT-2  ’  -O-Me-cAMP inhib-
its bTREK-1 K 
+   channels after activation of Epac2 is un-
known. This Epac-selective cAMP analogue inhibits K  ATP   
K 
+   channels of pancreatic      cells and cell lines through 
an Epac2-dependent mechanism, wherein activated Epac2 
interacts with the sulfonylurea receptor 1, a subunit of 
this inwardly rectifying K 
+   channel to reduce channel 
activity (  Kang et al., 2006  ). Further, it has recently been 
shown that Epac-selective cAMP activators function by 
sensitizing K  ATP   K 
+   channels to inhibition by ATP, shifting     Liu et al.  293
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